How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about avapritinib

Marketing authorisation indication

2.1 On 24 September 2020 the European Medicines Agency (EMA) granted conditional marketing authorisation for avapritinib for the treatment of unresectable or metastatic gastrointestinal stromal tumours (GIST) that have the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation.

Dosage in the marketing authorisation

2.2 The dosage schedule will be available in the summary of product characteristics [add hyperlink when available].

Price

2.3 Avapritinib costs £26,666.67 for 30 tablets (100 mg, 200 mg or 300 mg; excluding VAT; company submission).

The company has a commercial arrangement, which would have applied if the technology had been recommended.